InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,608.25
(
0.97%
)
US TECH 100
19,249.60
(
1.31%
)
Dow Jones
40,896.53
(
0.58%
)
Brent Oil
76.65
(
-0.94%
)
Bitcoin
61,012.21
(
2.59%
)
Post# of 252925
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 836
Posts 120312
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 151628

Friday, 11/30/2012 9:35:19 AM

Friday, November 30, 2012 9:35:19 AM

Post# of 252925
Teva forecasts $3.7-3.9B of worldwide Copaxone sales in 2013, which is a slight decrease from 2012. Teva has not given guidance on US Copaxone sales, specifically; however, if the historical 74% of sales in the US holds, then Teva expects 2013 US Copaxone sales of about $2.9B. The actual amount will depend on Copaxone price increases (which are a near certainty) and on competition from BG-12 and other oral agents.

Source: http://www.sec.gov/Archives/edgar/data/818686/000115752312006239/a50493505.htm

p.s. Copaxone has a worldwide gross margin of 90%, according to the above.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up